Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Smith HO et al. - Both the overall trial outcome, and specifically the excessively severe systemic toxicity of this regimen would prevent its future development in this exact form. The provocative PFS in a subset of individuals should encourage the development of alternative strategies designed to optimize the delivery of regional therapy in ovarian cancer management.

Related Articles

Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09    Relevance Score: 72%

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09    Relevance Score: 70%

Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09    Relevance Score: 70%

New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09    Relevance Score: 70%

New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09    Relevance Score: 70%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address